Takeda, CSL, Other Blood Plasma Firms Team On Hyperimmune COVID-19 Therapy
Executive Summary
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
You may also be interested in...
Pandemic Accelerates US FDA’s Use Of Real-World Data From Clinical Trial Design To Supply Chain
FDA’s Amy Abernethy describes how agency’s use of real-world data has evolved in response to COVID-19 and the ‘a-ha’ moment of leveraging different data sources to understand the coronavirus. Takeda R&D President Andrew Plump notes difficulties with platform trials and limitations on data sharing.
Convalescent Plasma EUA Will Not Complicate Hyperimmune Globulin Product Development, Sponsors Say
US FDA authorization will further boost already-high demand for plasma from individuals recovered from COVID-19 and increase competition for donors, NYU’s Arthur Caplan predicts, but CoVIg-19 Plasma Alliance and Emergent BioSolutions say they do not expect EUA to impact either product supply or enrollment in upcoming randomized trials of their H-Ig products.
Deal Watch: Alnylam/Dicerna Pact Addresses IP Questions Around Primary Hyperoxaluria Programs
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.